Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Dr Qiang Liu is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single case is being reviewed by 1 distinct examiner, SCHACHERMEYER, SAMANTHA LYNN. The prosecution is situated within 1 distinct art unit, indicating a concentrated technical focus for the company's current patent filings. With only 1 pending office action, the company's immediate interaction with the patent office is limited to this specific matter.
SCHACHERMEYER, SAMANTHA LYNN is designated as the busiest examiner for the portfolio, as they are responsible for the 1 pending office action currently on record. This examiner's role is central to the company's immediate patent outcomes in the Biotechnology & Pharmaceuticals field. The alignment of the examiner and the art unit for the 1 pending action suggests a streamlined prosecution path without the complexity of multiple examiner viewpoints. Practitioners can focus their strategy entirely on the requirements and past patterns of SCHACHERMEYER, SAMANTHA LYNN within this single art unit. This focused approach allows for a deep dive into the examiner's specific technical expectations.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHACHERMEYER, SAMANTHA LYNN | 1 | 35.7% | +70.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18771811 | Deblocking chromatography and cassette for isolating nucleic acids from liquid biopsy samples | SCHACHERMEYER, SAMANTHA LYNN | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18771811 | Deblocking chromatography and cassette for isolating nucleic acids from liquid biopsy samples | SCHACHERMEYER, SAMANTHA LYNN | 1693 | §102§103§112DP | Non-Final OA | — | Pending | Jul 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDr Qiang Liu has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Samantha Lynn Schachermeyer has the most, with 1 of Dr Qiang Liu's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.